qlosi
Qlosi (Pilocarpine Hydrochloride) is a cholinergic receptor agonist used to treat Head and Neck Neoplasms, Xerostomia, Angle-Closure Glaucoma, Mydriasis.
Pilocarpine Hydrochloride · by Orasis Pharms
Available as a generic: Pilocarpine Hydrochloride
Key facts
- Active ingredient
- Pilocarpine Hydrochloride
- Drug class
- Cholinergic Receptor Agonist
- Form
- Solution
- Strength
- Pilocarpine Hydrochloride 0.4%
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- Manufacturer
- Orasis Pharms
- What the pharmacy pays
- ~$0.38 per ml — not your price
- FDA application
- NDA217836
What is Qlosi?
From the FDA label:QLOSI (pilocarpine hydrochloride ophthalmic solution) 0.4% is a sterile, clear, colorless to slightly yellowish and slightly viscous ophthalmic solution for topical ophthalmic use which has a pH between 5.1-6.1. The structural formula of pilocarpine hydrochloride is: The chemical name for pilocarpine hydrochloride is: 2(3 H )-Furanone, 3-ethyldihydro-4-[(1-methyl-1 H -imidazol-5-yl)- methyl]-monohydrochloride, (3 S -cis). Its molecular weight is 244.72 g/mol and its molecular formula is C 11 H 16 N 2 O 2 ∙ HCl. Each mL contains 0.4% (4 mg) of pilocarpine hydrochloride as the active ingredient, equivalent to 0.3% (3.4 mg) of pilocarpine free-base. The inactive ingredients in QLOSI are: hypromellose, sodium chloride, sodium hyaluronate, edetate disodium dihydrate, water for injection, and may also include sodium hydroxide and/or hydrochloric acid for pH adjustment. QLOSI does not contain an anti-microbial preservative. Chemical Structure
How to use
Instill one drop of QLOSI in each eye. This can be repeated a second time after 2 to 3 hours for an effect up to 8 hours. QLOSI can be administered on a daily basis, or as needed, up to twice each day. If more than one topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart. Discard single-patient-use vial after use. Instill one drop of QLOSI in each eye. This can be repeated a second time after 2 to 3 hours for an effect up to 8 hours. QLOSI can be administered on a daily basis, or as needed, up to twice each day. ( 2 )
Side effects
Most common adverse reactions (5% to 8%) are instillation site pain and headaches. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Orasis Pharmaceuticals Inc. at 1-866-ORASIS1 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. QLOSI was evaluated in 309 patients with presbyopia in two randomized, double-masked, vehicle-controlled studies (NEAR-1 and NEAR-2) of 15 days duration. The most commonly reported treatment-related adverse events in 5-8% of patients were instillation site pain, and headache. Ocular adverse reaction reported in 2-5% of patients was blurred vision. The majority of the adverse events were mild, transient and self-resolving.
Warnings
Important safety information
Blurred Vision : Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). Exercise caution in night driving and other hazardous occupations in poor illumination. ( 5.1 ) Risk of Retinal Detachment : Rare cases of retinal detachment have been reported with miotics. Examination of the retina is advised in all patients prior to initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss. ( 5.2 ) Iritis : Caution is advised in patients with iritis. ( 5.3 ) 5.1 Blurred Vision Miotics, including QLOSI, may cause accommodative spasm. Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). In addition, patients may experience temporary dim or dark vision with miotics, including QLOSI. Advise patients to exercise caution in night driving and other hazardous activities in poor illumination. 5.2 Risk of Retinal Detachment Rare cases of retinal detachment have been reported with miotics when used in susceptible individuals and those with pre-existing retinal disease. Examination of the retina is advised in all patients prior to the initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss. 5.3 Iritis QLOSI is not recommended to be used when iritis is present because adhesions (synechiae) may form between the iris and the lens. 5.4 Contact Lens Wear Contact lens wearers should be advised to remove their lenses prior to the instillation of QLOSI and to wait 10 minutes after dosing before reinserting their contact lenses. 5.5 Potential for Eye Injury or Contamination To prevent eye injury or contamination, avoid touching the tip of the single-patient-use vial to the eye or to any other surface.
Who should not take Qlosi
QLOSI is contraindicated in patients with known hypersensitivity to the active ingredient or to any of the excipients. Hypersensitivity ( 4 )
Overdose — what happens if you take too much
Systemic toxicity following topical ocular administration of pilocarpine is rare, but occasionally patients who are sensitive may develop sweating and gastrointestinal overactivity. Accidental ingestion can produce sweating, salivation, nausea, tremors and slowing of the pulse and a decrease in blood pressure. In moderate overdosage, spontaneous recovery is to be expected and is aided by intravenous fluids to compensate for dehydration. For patients demonstrating severe poisoning, atropine, the pharmacologic antagonist to pilocarpine, should be used.
U.S. Poison Control: call or text 1-800-222-1222 (free, 24/7). In an emergency call 911. From the FDA label; not medical advice.
Drug class
How this class works, per Muscarinic Agonists - StatPearls - NCBI Bookshelf.
May treat (source: NIH RxClass)
See how Qlosi ranks — best-rated cholinergic receptor agonist for:
Dosage forms
Solution
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Qlosi treat?
- Qlosi (Pilocarpine Hydrochloride) may be used to treat head and neck neoplasms, xerostomia, angle-closure glaucoma, mydriasis, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How does Qlosi work?
- Qlosi is a cholinergic receptor agonist. Cholinergic receptor agonists mimic acetylcholine and switch on its receptors, triggering the body's "rest and digest" responses. This boosts effects like saliva and tear flow, bladder and bowel emptying, and pupil constriction.
- How much does Qlosi cost?
- Nobody can tell you what you will pay — your price is set by your insurer's formulary, your deductible and the pharmacy's markup, and none of those are published. What IS published is what the pharmacy paid to acquire it: about $0.38 per ml, per the CMS NADAC survey. Treat that as the floor, not the quote — ask the pharmacist for the cash price as well as your copay, because for cheap generics the cash price often wins.
- Is there a coupon or discount for Qlosi?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Qlosi. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Qlosi?
- Qlosi is marketed by Orasis Pharms. You can see Orasis Pharms's full profile, rating, and other products on pharmaranks.
- Is Qlosi a brand-name or generic drug?
- Qlosi is a brand-name product with the active ingredient Pilocarpine Hydrochloride. Lower-cost generic equivalents containing Pilocarpine Hydrochloride are available — ask your pharmacist.
- Is Qlosi available over the counter?
- No. Qlosi is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Qlosi come in?
- Qlosi is currently marketed as solution, per the FDA's National Drug Code Directory.
- What class of drug is Qlosi?
- Qlosi is classified as cholinergic receptor agonist, per the FDA's Established Pharmacologic Class.
- Is Qlosi FDA-registered?
- Qlosi is on record with the U.S. FDA under application number NDA217836. You can verify this on its official FDA label.
- Is Qlosi safe?
- There's no single safe-or-not verdict, and we don't yet have a composite recall-safety score for Qlosi. Review its FDA-label side effects and warnings below, and always consult a licensed professional.
- What are the side effects of Qlosi?
- Qlosi's side effects are taken directly from its FDA label. From the label: Most common adverse reactions (5% to 8%) are instillation site pain and headaches. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Orasis Pharmaceuticals Inc. at 1-866-ORASIS1 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.… Both common and serious reactions are documented in full on this page. This is general reference from the FDA, not medical advice — always consult a professional.
Clinical content sourced from the FDA label via openFDA (U.S. FDA). View the FDA label on DailyMed → Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
Reviews
No reviews yet. Be the first to write one.
People also viewed
isopto carpine
Pilocarpine Hydrochloride
chantix
Varenicline Tartrate
miostat
Carbachol
pilocarpine hydrochloride
Pilocarpine Hydrochloride
salagen
Pilocarpine Hydrochloride
tyrvaya
Varenicline Tartrate
Compare Qlosi head-to-head
More cholinergic receptor agonist drugs
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
qlosi
New